Management of immunosuppressive therapy in kidney transplant recipients with COVID-19. A multicentre national study derived from the Spanish Society of Nephrology COVID registry

CONCLUSIONS: The management of immunosuppressive therapy after diagnosis of COVID19 was primarily based on discontinuation of mycophenolic acid with very discrete reductions or discontinuations of calcineurin inhibitors. This immunosuppression management did not influence renal function or changes in anti-HLA antibodies 6 months after diagnosis.PMID:37661514 | DOI:10.1016/j.nefroe.2023.08.004

Source: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia - September 4, 2023 Category: Urology & Nephrology Authors: Mar ía O López-Oliva Isabel P érez-Flores Mar ía Molina Mar ía José Aladrén Hernando Trujillo Dolores Redondo-Pach ón Ver ónica López Carme Facundo Florentino Villanego Marisa Rodr íguez Maria Carmen Ruiz Paula Ant ón Alba Rivas-Oural Sheila C Source Type: research